70%Confidence
0Views
SEC EDGARSource
2026-04-08Date
Summary
Plus Therapeutics filed an 8-K, potentially announcing clinical milestones or financing rounds critical for its oncology pipeline. Biotech startups rely on such disclosures to attract investment and partnerships.
Actionable: Investigate the filing for catalyst events that could affect stock liquidity and valuation.
AI Confidence: 70%
Data Points
companyPLUS THERAPEUTICS, INC. (PSTV) (CIK 0001095981)
form8-K
date2026-04-08
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now